Look at: ECB President Christine Lagarde speaks following charge determination

Look at: ECB President Christine Lagarde speaks following charge determination


[The stream is slated to start at 8:45 a.m. ET. Please refresh the page if you do not see a player above at that time.]

European Central Bank  President Christine Lagarde is due to give a push conference following the bank’s most recent monetary coverage selection.

The bank introduced that it was getting its primary fee up by 25 basis points to 3.5%, diverging from a U.S. Federal Reserve conclusion to pause its possess hikes on Wednesday.

Subscribe to CNBC on YouTube. 



Supply

Stocks making the biggest moves after hours: Cisco, Flutter Entertainment, Firefly and more
Finance

Stocks making the biggest moves after hours: Cisco, Flutter Entertainment, Firefly and more

Check out the companies making headlines in after-hours trading. Cisco — Shares of Cisco gained more than 7% in extended trading after the networking company posted better-than-expected profit and revenue for its fiscal first quarter. Cisco earned $1 per share, excluding items, on $14.88 billion in revenue, while analysts polled by LSEG expected 98 cents […]

Read More
Boston Fed President Collins advocates holding rates steady, sees ‘high bar’ for further cuts
Finance

Boston Fed President Collins advocates holding rates steady, sees ‘high bar’ for further cuts

Key Points Boston Fed President Susan Collins said she will be reluctant to support further rate cuts anytime soon with inflation still high and policymakers hampered by a lack of data. “I see several reasons to have a relatively high bar for additional easing in the near term,” said Collins, a voter this year on […]

Read More
Stocks making the biggest moves midday: Goldman Sachs, AMD, Oklo, Circle Internet & more
Finance

Stocks making the biggest moves midday: Goldman Sachs, AMD, Oklo, Circle Internet & more

Check out the companies making the biggest moves midday: Alkermes — The biotech company dropped 9% as traders weighed phase 2 trial results for its ALKS 2680 drug, which aims to treat narcolepsy. While the company will be advancing the drug to a Phase 3 trial, a higher range of doses or a split dosing […]

Read More